Literature DB >> 20512889

Pharmacokinetic mapping for lesion classification in dynamic breast MRI.

Matthias C Schabel1, Glen R Morrell, Karen Y Oh, Cheryl A Walczak, R Brad Barlow, Leigh A Neumayer.   

Abstract

PURPOSE: To prospectively investigate whether a rapid dynamic MRI protocol, in conjunction with pharmacokinetic modeling, could provide diagnostically useful information for discriminating biopsy-proven benign lesions from malignancies.
MATERIALS AND METHODS: Patients referred to breast biopsy based on suspicious screening findings were eligible. After anatomic imaging, patients were scanned using a dynamic protocol with complete bilateral breast coverage. Maps of pharmacokinetic parameters representing transfer constant (K(trans)), efflux rate constant (k(ep)), blood plasma volume fraction (v(p)), and extracellular extravascular volume fraction (v(e)) were averaged over lesions and used, with biopsy results, to generate receiver operating characteristic curves for linear classifiers using one, two, or three parameters.
RESULTS: Biopsy and imaging results were obtained from 93 lesions in 74 of 78 study patients. Classification based on K(trans) and k(ep) gave the greatest accuracy, with an area under the receiver operating characteristic curve of 0.915, sensitivity of 91%, and specificity of 85%, compared with values of 88% and 68%, respectively, obtained in a recent study of clinical breast MRI in a similar patient population.
CONCLUSION: Pharmacokinetic classification of breast lesions is practical on modern MRI hardware and provides significant accuracy for identification of malignancies. Sensitivity of a two-parameter linear classifier is comparable to that reported in a recent multicenter study of clinical breast MRI, while specificity is significantly higher.

Entities:  

Mesh:

Year:  2010        PMID: 20512889      PMCID: PMC4657573          DOI: 10.1002/jmri.22179

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  36 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.

Authors:  Christiane K Kuhl; Hans H Schild; Nuschin Morakkabati
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

3.  Meta-analysis of MR imaging in the diagnosis of breast lesions.

Authors:  Nicky H G M Peters; Inne H M Borel Rinkes; Nicolaas P A Zuithoff; Willem P T M Mali; Karel G M Moons; Petra H M Peeters
Journal:  Radiology       Date:  2007-11-16       Impact factor: 11.105

4.  Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging.

Authors:  R E Port; M V Knopp; U Hoffmann; S Milker-Zabel; G Brix
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 5.  Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.

Authors:  Nola Hylton
Journal:  J Clin Oncol       Date:  2006-07-10       Impact factor: 44.544

6.  Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours.

Authors:  S Mussurakis; D L Buckley; P J Drew; J N Fox; P J Carleton; L W Turnbull; A Horsman
Journal:  Clin Radiol       Date:  1997-07       Impact factor: 2.350

7.  Temporal sampling requirements for the tracer kinetics modeling of breast disease.

Authors:  E Henderson; B K Rutt; T Y Lee
Journal:  Magn Reson Imaging       Date:  1998-11       Impact factor: 2.546

8.  The significance of atypical lobular hyperplasia at percutaneous breast biopsy.

Authors:  Karen Dmytrasz; Paul Ian Tartter; Howard Mizrachy; Lynn Chinitz; Sharon Rosenbaum Smith; Alison Estabrook
Journal:  Breast J       Date:  2003 Jan-Feb       Impact factor: 2.431

9.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

Review 10.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors:  J P B O'Connor; A Jackson; G J M Parker; G C Jayson
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

View more
  19 in total

1.  A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings.

Authors:  Luminita A Tudorica; Karen Y Oh; Nicole Roy; Mark D Kettler; Yiyi Chen; Stephanie L Hemmingson; Aneela Afzal; John W Grinstead; Gerhard Laub; Xin Li; Wei Huang
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

2.  Influence of scan duration on the estimation of pharmacokinetic parameters for breast lesions: a study based on CAIPIRINHA-Dixon-TWIST-VIBE technique.

Authors:  Wen Hao; Bin Zhao; Guangbin Wang; Cuiyan Wang; Hui Liu
Journal:  Eur Radiol       Date:  2014-10-17       Impact factor: 5.315

3.  Feasibility analysis of early temporal kinetics as a surrogate marker for breast tumor type, grade, and aggressiveness.

Authors:  Laura Heacock; Alana A Lewin; Yiming Gao; James S Babb; Samantha L Heller; Amy N Melsaether; Neeti Bagadiya; Sungheon G Kim; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2017-11-27       Impact factor: 4.813

4.  Comparison of conventional DCE-MRI and a novel golden-angle radial multicoil compressed sensing method for the evaluation of breast lesion conspicuity.

Authors:  Laura Heacock; Yiming Gao; Samantha L Heller; Amy N Melsaether; James S Babb; Tobias K Block; Ricardo Otazo; Sungheon G Kim; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2016-11-17       Impact factor: 4.813

5.  Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial.

Authors:  Anna G Sorace; Savannah C Partridge; Xia Li; Jack Virostko; Stephanie L Barnes; Daniel S Hippe; Wei Huang; Thomas E Yankeelov
Journal:  J Med Imaging (Bellingham)       Date:  2018-01-22

6.  Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.

Authors:  Wei Huang; Luminita A Tudorica; Xin Li; Sunitha B Thakur; Yiyi Chen; Elizabeth A Morris; Ian J Tagge; Maayan E Korenblit; William D Rooney; Jason A Koutcher; Charles S Springer
Journal:  Radiology       Date:  2011-08-09       Impact factor: 11.105

7.  In vivo evaluation of a breast-specific magnetic resonance guided focused ultrasound system in a goat udder model.

Authors:  A Payne; N Todd; E Minalga; Y Wang; M Diakite; R Hadley; R Merrill; R Factor; L Neumayer; D L Parker
Journal:  Med Phys       Date:  2013-07       Impact factor: 4.071

8.  A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer.

Authors:  Xia Li; E Brian Welch; Lori R Arlinghaus; A Bapsi Chakravarthy; Lei Xu; Jaime Farley; Mary E Loveless; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie A Means-Powell; Vandana G Abramson; Ana M Grau; John C Gore; Thomas E Yankeelov
Journal:  Phys Med Biol       Date:  2011-08-12       Impact factor: 3.609

9.  Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC.

Authors:  Antonella Petrillo; Roberta Fusco; Mario Petrillo; Vincenza Granata; Mario Sansone; Antonio Avallone; Paolo Delrio; Biagio Pecori; Fabiana Tatangelo; Gennaro Ciliberto
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

10.  Whole-lesion histogram and texture analyses of breast lesions on inline quantitative DCE mapping with CAIPIRINHA-Dixon-TWIST-VIBE.

Authors:  Kun Sun; Hong Zhu; Weimin Chai; Ying Zhan; Dominik Nickel; Robert Grimm; Caixia Fu; Fuhua Yan
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.